Implementing Decision (EU) 2020/1729 is amended as follows:
in Article 1(2), the following point (f) is added:
‘(f) methicillin-resistant Staphylococcus aureus (MRSA).’;
in Article 3, paragraph 2 is replaced by the following:
‘(2) National reference laboratories for AMR, or other laboratories designated by the competent authority in accordance with Article 37 of Regulation (EU) 2017/625, shall be responsible for carrying out:
the antimicrobial susceptibility testing of bacterial isolates, referred to in paragraph 1 of this Article, in accordance with the technical requirements set out in Part A, point 4, of the Annex;
the specific monitoring of ESBL-, AmpC- or CP-producing E. coli in accordance with the technical requirements set out in Part A, point 5, of the Annex;
the specific monitoring of MRSA in accordance with the technical requirements set out in Part A, point 5a, of the Annex;
the alternative method referred to in Part A, point 6, of the Annex.’
;
The Annex is amended in accordance with the Annex to this Decision.